Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 801–900 of 1,035
Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication
Gonnissen, A., Isebaert, S. F., & Haustermans, K. M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713979 · Cited by 119
“As for the latter, the tumor vasculature is characterized by poorly organized, immature and leaky blood vessels resulting in impaired blood supply and thus impaired drug delivery [127].”
BackgroundVascular update: Morphogenesis, tumors, malformations, and molecular dimensions
Cohen, M. M. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31333 · Cited by 113
Fang, P., Hu, J., Cheng, Z., Liu, Z., Wang, J., & Jiao, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049717 · Cited by 112
“Bevacizumab may also help normalize tumor vasculature, improving oxygenation and the delivery of cytotoxic drugs [14].”
BackgroundBullitt, E., Zeng, D., Mortamet, B., Ghosh, A., Aylward, S. R., Lin, W., Marks, B. L., & Smith, K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.022 · Cited by 110
“2005; Jain 2005; Li et. al.”
de Oliveira, R. L., Hamm, A., & Mazzone, M. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.001 · Cited by 133
Reardon, D. A., Neyns, B., Weller, M., Tonn, J. C., Nabors, B., & Stupp, R. (2011) · Future Oncology · doi:10.2217/fon.11.8 · Cited by 129
Joosten, S. C., Hamming, L. C., Soetekouw, P. M. M. B., Aarts, M. J. B., Veeck, J., van Engeland, M., & Tjan‐Heijnen, V. C. G. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.11.002 · Cited by 119
“Although normalization of the tumor vasculature leads to better oxygen and nutrient supply and thus accelerated tumor growth, it also leads to a more effective drugdelivery and immune-response, which counteracts these effects [98].”
BackgroundIncidence and management of bevacizumab-related toxicities in colorectal cancer
Saif, M. W., & Mehra, R. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.4.553 · Cited by 111
“Vessel normalisation also likely improves oxygenation of the tumour and the availability of reactive oxygen species, thereby providing a radiosensitising effect [6].”
BackgroundLi, W., Zhou, Z., Zhou, X., Khoo, B. L., Gunawan, R., Chin, Y. R., Zhang, L., Yi, C., Guan, X., & Yang, M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202609 · Cited by 119
VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
Cao, Y. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.114 · Cited by 109
Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
Pikor, L. A., Bell, J. C., & Diallo, J. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.004 · Cited by 124
“Hallmarks of the Tumor Microenvironment Promote Viral Replication Vascular Endothelial Growth Factor A (VEGF-A) is overexpressed in many human tumors and drives the formation of highly dysfunctional, hyperpermeable, and tortuous tumor vasculature that results in inadequate perfusion, hypoxia, and high interstitial flu…”
BackgroundTargeting the tumor microenvironment: Potential strategy for cancer therapeutics
Babar, Q., Saeed, A., Tabish, T. A., Sarwar, M., & Thorat, N. D. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166746 · Cited by 125
Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery
Cooney, M. M., van Heeckeren, W., Bhakta, S., Ortiz, J., & Remick, S. C. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0663 · Cited by 112
“Figure 2 Schema depicting tumor vascular normalization as proposed by Jain.10 The addition of an antivascular or antiangiogenic agent prunes abnormal and immature tumor vessels, transiently ‘normalizing’ tumor blood flow resulting in improved drug delivery of cytotoxic chemotherapy. Reprinted with permission from AAAS…”
BackgroundQazi, H., Shi, Z.-D., & Tarbell, J. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020348 · Cited by 109
“It has, however, been theorized that spatial and temporal heterogeneities in flow, elevated fluid flow at the periphery, and fluid shear stress may modulate metastasis, growth, and invasion [1,15,16].”
BackgroundInfluentialAdverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Fakih, M., & Vincent, M. (2010) · Current Oncology · doi:10.3747/co.v17is1.615 · Cited by 109
Egfl7 Promotes Tumor Escape from Immunity by Repressing Endothelial Cell Activation
Delfortrie, S., Pinte, S., Mattot, V., Samson, C., Villain, G., Caëtano, B., Lauridant, G., Baranzelli, M., Bonneterre, J. M., Trottein, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1301 · Cited by 117
Xue, Q., Hopkins, B., Perruzzi, C., Udayakumar, D., Sherris, D., & Benjamin, L. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2058 · Cited by 106
“Notably, vascular normalization is proposed to be a key component of the ability of bevacizumab (Avastin) to synergize with chemotherapy and radiation (2).”
Small GTPase R-Ras Regulates Integrity and Functionality of Tumor Blood Vessels
Sawada, J., Urakami, T., Li, F., Urakami, A., Zhu, W., Fukuda, M., Li, D. Y., Ruoslahti, E., & Komatsu, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.013 · Cited by 109
“The plasma leakage from tumor vessels elevates the interstitial fluid pressure within the tumor and significantly reduces the diffusion of therapeutic agents (Jain, 2005).”
InfluentialFrom Homogeneous to Fractal Normal and Tumorous Microvascular Networks in the Brain
Risser, L., Plouraboué, F., Steyer, A., Cloetens, P., Duc, G. L., & Fonta, C. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600332 · Cited by 109
“…a broad range of fundamental and clinical subjects such as normal and pathologic vascular development (Hobbs et al, 1998; Yuan et al, 1996), functional imaging interpretation (Malonek and Grinvald, 1996), micro-circulatory modeling (Lichtenbeld et al, 1996), and therapeutic strategies (Jain, 2005).”
Role of Macrophage Polarization in Tumor Angiogenesis and Vessel Normalization
Chen, P., & Bonaldo, P. (2013) · International review of cytology · doi:10.1016/b978-0-12-407704-1.00001-4 · Cited by 126
Dobosz, M., Ntziachristos, V., Scheuer, W., & Strobel, S. (2014) · Neoplasia · doi:10.1593/neo.131848 · Cited by 110
Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics
Lin, Q., & Yun, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.12.12347 · Cited by 118
Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma
Guo, X., Li, D., Sun, K., Wang, J., Liu, Y., Song, J., Zhao, Q., Zhang, S., Deng, W.-J., Zhao, X., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0966-0 · Cited by 118
“Bevacizumab is a recombinant, humanized monoclonal antibody that binds VEGF with high affinity and has been approved by the FDA for treatment of certain late-stage cancers [4, 5].”
BackgroundGerber, H., Wu, X., Yu, L., Wiesmann, C., Liang, X. H., Lee, C. V., Fuh, G., Olsson, C., Damico, L. A., Xie, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611492104 · Cited by 118
Targeting Hypoxic Cells through the DNA Damage Response
Olcina, M., Lecane, P. S., & Hammond, E. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0286 · Cited by 108
“For this reason, the value of Chk inhibitors to target hypoxic regions will probably be in combination with agents known to induce either reoxygenation or vessel normalization (46).”
BackgroundDoes iron have a role in breast cancer?
Huang, X. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70200-6 · Cited by 108
Vasohibin-1 Expression in Endothelium of Tumor Blood Vessels Regulates Angiogenesis
Hosaka, T., Kimura, H., Heishi, T., Suzuki, Y., Miyashita, H., Ohta, H., Sonoda, H., Moriya, T., Suzuki, S., Kondo, T., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080788 · Cited by 107
“Maturation of tumor vasculature enhances the efficacy of cytotoxic anti-cancer therapies, as it increases the delivery of anti-cancer drugs to the tumor cells.(35) We therefore anticipated that exogenous VASH1 should enhance the efficacy of cytotoxic anticancer therapies.”
BackgroundLunt, S. J., Kalliomaki, T. M., Brown, A., Yang, V. X., Milosevic, M., & Hill, R. P. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-2 · Cited by 106
“Elevated tumour IFP plays a role in the pathophysiological microenvironment that characterises solid tumours contributing to disease progression and therapeutic resistance [3,6-9].”
Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy
Wu, J., Tang, Y., & Liang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172042 · Cited by 105
Xu, D., Li, Y., Yin, S., & Huang, F. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00926b · Cited by 111
Mechanisms of Vessel Regression: Toward an Understanding of the Resolution of Angiogenesis
Wietecha, M. S., Cerny, W. L., & DiPietro, L. A. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_287 · Cited by 121
Radionuclide carriers for targeting of cancer
Sofou, S. (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s2736 · Cited by 125
“In a different approach, because it is the larger tumors that develop neovasculature networks, combination of active targeting and passive targeting was studied by Line and colleagues (Line et al 2005). For active targeting multivalent RDG sequences were used that were attached on relatively large delivery carriers to…”
InfluentialHofmann, M., Guschel, M., Bernd, A., Bereiter-Hahn, J., Kaufmann, R., Tandi, C., Wiig, H., & Kippenberger, S. (2006) · Neoplasia · doi:10.1593/neo.05469 · Cited by 106
Wang, X., Sun, Q., & Pei, J. (2018) · Micromachines · doi:10.3390/mi9100493 · Cited by 106
“Therefore, another concept for tumor anti-angiogenic therapy is to study the normalization of tumor vasculature, which can temporarily “normalize” the abnormal structure and function of tumor vasculature into the functionally normal blood vessels by using certain antiangiogenic agents to make it more efficient for oxy…”
BackgroundVecchione, L., Jacobs, B., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.021 · Cited by 119
Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
Tailor, T. D., Hanna, G., Yarmolenko, P. S., Dreher, M. R., Betof, A. S., Nixon, A. B., Spasojevic, I., & Dewhirst, M. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0856 · Cited by 106
“This impedes the ability of systemic therapies, particularly macromolecules and liposomes, which rely on convection for transvascular transport, to traverse the endothelial barrier and penetrate the interstitium (4, 5).”
BackgroundResultInfluentialGoedegebuure, R. S. A., de Klerk, L. K., Bass, A. J., Derks, S., & Thijssen, V. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03107 · Cited by 123
“For instance, radiotherapy can exert opposing effects on tumor vascularization and perfusion depending on dose-scheduling (8, 9).”
BackgroundEndothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy
Cartier, A., Leigh, T., Liu, C. H., & Hla, T. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906246117 · Cited by 112
Regulation of vascular integrity
Murakami, M., & Simons, M. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0463-2 · Cited by 120
“The conversion of a typically abnormal tumor vasculature characterized by excessive leakiness and inefficient perfusion to an efficient and wellsealed system results in improved tumor perfusion and facilitates delivery of cytotoxic compounds [3, 4].”
Chinnasamy, D., Tran, E., Yu, Z., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3913 · Cited by 106
“Multiple studies have shown that antiangiogenic agents can remodel the tumor vasculature and improve drug penetration into tumors (37, 38) and also enhance active immunotherapy through increasing the infiltration of immune cells into tumors (39).”
BackgroundBiology of the apelin-APJ axis in vascular formation
Kidoya, H., & Takakura, N. (2012) · The Journal of Biochemistry · doi:10.1093/jb/mvs071 · Cited by 111
Combination antiangiogenic therapy and radiation in head and neck cancers
Hsu, H.-W., Wall, N. R., Hsueh, C.-T., Kim, S., Ferris, R. L., Chen, C.-S., & Mirshahidi, S. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.10.003 · Cited by 107
“[21,22].”
BackgroundAdair, T. H., & Montani, J. (2010) · Colloquium Series on Integrated Systems Physiology From Molecule to Function · doi:10.4199/c00017ed1v01y201009isp010 · Cited by 139
Kudo, M., Ueshima, K., Saeki, I., Ishikawa, T., Inaba, Y., Morimoto, N., Aikata, H., Tanabe, N., Wada, Y., Kondo, Y., et al. (2023) · Liver Cancer · doi:10.1159/000531377 · Cited by 115
“Anti-VEGF agents improve drug delivery by normalizing tumor vasculature, which is achieved through the normalization of interstitial pressure, microvascular density, or vascular permeability [9 – 11 , 15].”
BackgroundResultTargeting endothelial permeability in the EPR effect
Lahooti, B., Akwii, R. G., Zahra, F. T., Sajib, M. S., Λάμπρου, Μ., Alobaida, A., Lionakis, M. S., Mattheolabakis, G., & Mikelis, C. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.039 · Cited by 119
Liu, B., Lee, K.-W., Anzo, M., Zhang, B., Zi, X., Tao, Y., Shiry, L., Pollak, M., Lin, S., & Cohen, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209977 · Cited by 107
“IGFBP-3 is induced by hypoxia (Grimberg et al., 2005) and may be involved in the normalization of tumor vasculature, modulating the abnormal structure and function of tumor vasculature (Jain, 2005).”
BackgroundEnzymatic preparation of κ-carrageenan oligosaccharides and their anti-angiogenic activity
Yao, Z., Wu, H., Zhang, S., & Du, Y. (2013) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2013.09.055 · Cited by 114
“In cancer, the vasculature s highly disorganized and resulted in poor blood flow and high ascular permeability, which may lead to increased potential for etastasis (Baluk, Hashizume, & McDonald, 2005; Gerber & Ferrara, 005; Jain, 2005).”
BackgroundTSU68 Prevents Liver Metastasis of Colon Cancer Xenografts by Modulating the Premetastatic Niche
Yamamoto, M., Kikuchi, H., Ohta, M., Kawabata, T., Hiramatsu, Y., Kondo, K., Baba, M., Kamiya, K., Tanaka, T., Kitagawa, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1748 · Cited by 105
“Understanding of these detailed mechanisms provided the rationale for combination therapy using antiangiogenic agents and cytotoxic chemotherapy (4, 7 ). Nowadays, various other kinds of antiangiogenic agents, such as anti-VEGF receptor antibodies (8), soluble VEGF receptors (9), and VEGF receptor tyrosine kinase inhi…”
BackgroundAntiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
Claes, A., Wesseling, P., Jeuken, J., Maass, C., Heerschap, A., & Leenders, W. P. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0552 · Cited by 105
“Based on the results of clinical trials with other tumor types (6), it is postulated that this reduction of vessel leakage and concomitant reduction of interstitial fluid pressure (called vessel normalization) will improve biodistribution of cytotoxic compounds to tumor cells (23).”
BackgroundChen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Jiang, X., Khan, M. A., Tian, W., Beilke, J., Natarajan, R., Kosek, J., Yoder, M. C., Semenza, G. L., & Nicolls, M. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46192 · Cited by 104
Ueda, S., Saeki, T., Osaki, A., Yamane, T., & Kuji, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0874 · Cited by 103
“In hypoxic environments, resistance to VEGF blockade could be associated with the activation of the hypoxia-inducible factor (HIF)-1a, which induces the release of hypoxia-mediated proangiogenic factors, such as VEGF, bFGF, and TGFb, from tumor cells (32, 33).”
BackgroundIntravoxel incoherent motion MRI as a means to measure in vivo perfusion: A review of the evidence
Federau, C. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3780 · Cited by 117
“The authors found the increase consistent with the known normalization of tumor vasculature after antiangiogenic therapy.(115) In addition, they found that f was inversely correlated with alpha‐fetoprotein serum level, which is known to correlate with low survival.”
ResultChoi, H. Y., Yang, G., Dayem, A. A., Saha, S. K., Kim, K., Yoo, Y.-B., Hong, K., Kim, J., Yee, C., Lee, K., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1071-2 · Cited by 111
“Moreover, ionized calcium levels in the whole blood [14, 43], a measure of metastasis, were significantly increased in CT + SS-injected mice (Fig.”
BackgroundKitadai, Y., Sasaki, T., Kuwai, T., Nakamura, T., Bucana, C. D., & Fidler, I. J. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060653 · Cited by 104
“mostly active against immature vessels,(46) ie, normalization of the tumor vasculature.(47) Because imatinib inhibits pericyte coverage on tumor vasculature, it will be very interesting to determine whether the combined inhibition of PDGF-R and VEGF receptor signaling may produce synergistic antivascular effects.”
BackgroundNacev, A., Komaee, A., Sarwar, A., Probst, R., Kim, S. H., Emmert-Buck, M., & Shapiro, B. (2012) · IEEE Control Systems · doi:10.1109/mcs.2012.2189052 · Cited by 104
“Chemotherapy injected into the blood must diffuse from blood vessels into tumors; since metastatic cells are further away from blood vessels, they are likely subjected to lower concentrations of chemotherapy, as compared to healthy cells that would receive higher doses [231], [268].”
BackgroundKoh, T. S., Thng, C. H., Lee, P. S., Hartono, S., Rumpel, H., Goh, B. C., & Bisdas, S. (2008) · Radiology · doi:10.1148/radiol.2483071958 · Cited by 104
Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics
Navarro, P., Bueno, M. J., Zagorac, I., Mondejar, T., Sanchez, J., Mourón, S., Muñoz, J., Gómez-López, G., Jimenez-Renard, V., Mulero, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.052 · Cited by 102
“Rapidly growing tumors are supported by abnormal vessels (Jain, 2005), leading to hypoxia that triggers the transcriptional program that fuels the Warburg effect (Jain, 2005; Ostergaard et al.”
BackgroundInfluentialCao, Z., Shang, B., Zhang, G., Miele, L., Sarkar, F. H., Wang, Z. P., & Zhou, Q. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.08.001 · Cited by 109
“Vascular normalization has emerged as a new option for anti-cancer therapy [178-180].”
Lee, H. K., Chauhan, S. K., Kay, E., & Dana, R. (2011) · Blood · doi:10.1182/blood-2010-09-306928 · Cited by 107
Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0742-t · Cited by 103
“Downregulation of VEGF signaling in tumors is pursuedas anopportunity to restore vasculature to normalcy, a state requiring both spatial and temporal control of VEGF levels (27).”
BackgroundNormalizing Tumor Microenvironment Based on Photosynthetic Abiotic/Biotic Nanoparticles
Zheng, D., Li, B., Xu, L., Zhang, Q.-L., Fan, J.-X., Li, C.-X., & Zhang, X.-Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b02977 · Cited by 103
Tumor Endothelial Heterogeneity in Cancer Progression
Maishi, N., Annan, D. A., Kikuchi, H., Hida, Y., & Hida, K. (2019) · Cancers · doi:10.3390/cancers11101511 · Cited by 109
“only suppresses the growth of tumors, it also normalizes blood vessel structures and improves the delivery of oxygen and drugs, which potentially affects both radiotherapy and chemotherapy [6,7].”
BackgroundWang, Q., Gao, J., Di, W. J., & Wu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02576-x · Cited by 107
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 108
Du, S., Yang, Z., Lu, X., Yousuf, S., Zhao, M., Li, W., Miao, J., Wang, X., Heng, Y., Zhu, X., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01988-y · Cited by 110
“Tumor neo-vessels grow highly tortuous, leaky and irregular, resulting in abnormal and poorly functioning vasculature [15].”
High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer
Vella, G., Guelfi, S., & Bergers, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.736670 · Cited by 121
Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies
Zhang, Z., Wang, T., Wang, X.-F., Zhang, Y., Song, S., & Ma, C. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106036 · Cited by 115
Current status of angiogenesis inhibitors combined with radiation therapy
Nieder, C., Wiedenmann, N. E., Andratschke, N. H., & Molls, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.03.006 · Cited by 113
Interleukin 21: combination strategies for cancer therapy
Skak, K., Kragh, M., Hausman, D. F., Smyth, M. J., & Sivakumar, P. V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2482 · Cited by 110
“Cytostatics and TKIs could be attractive partners for IL21 for various reasons: TKIs may normalize the tumour vasculature owing to their anti-angiogenic effect”
BackgroundHypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Oliver, L., Olivier, C., Marhuenda, F., Campone, M., & Vallette, F. M. (2009) · Current Molecular Pharmacology · doi:10.2174/1874467210902030263 · Cited by 111
“The overall result would be an adaptive effect, which would include angiogenesis [48].”
BackgroundAntiangiogenic Therapies: Going beyond Their Limits
Moserle, L., Jiménez-Valerio, G., & Casanovas, O. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0199 · Cited by 102
Acute Myeloid Leukemia and the Bone Marrow Niche—Take a Closer Look
Behrmann, L., Wellbrock, J., & Fiedler, W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00444 · Cited by 118
Tumor Starvation Induced Spatiotemporal Control over Chemotherapy for Synergistic Therapy
Zhang, M., Li, C., Wang, S., Liu, T., Song, X., Yang, X., Feng, J. X., & Zhang, X. (2018) · Small · doi:10.1002/smll.201803602 · Cited by 103
Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies
Annese, T., Tamma, R., Ruggieri, S., & Ribatti, D. (2019) · Cancers · doi:10.3390/cancers11030381 · Cited by 111
Liu, Y., Zhou, J., Li, Q., Li, L., Jia, Y., Geng, F., Zhou, J., & Yin, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.019 · Cited by 102
Akter, S., Rahman, M. A., Hasan, M. N., Akhter, H., Noor, P., Islam, R., Shin, Y., Rahman, M. H., Gazi, M. S., Huda, M. N., et al. (2022) · Cells · doi:10.3390/cells11040650 · Cited by 125
“Angiogenesis is the process of forming new blood vessels, which enables nutrients and oxygen to enter the surrounding tissues, thus promoting tumor cell proliferation, invasion, and metastasis [87,88].”
BackgroundPoulsen, H. S., Grunnet, K., Mau‐Sørensen, M., Olsen, P., Hasselbalch, B., Nelausen, K. M., Kosteljanetz, M., & Lassen, U. (2008) · Acta Oncologica · doi:10.1080/02841860802537924 · Cited by 104
“The latter would increase irinotecan penetration into the tumour and all these mechanisms would facilitate increased tumour cell death [8,9,12].”
BackgroundNakahara, T., Norberg, S. M., Shalinsky, D. R., Hu-Lowe, D. D., & McDonald, D. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0923 · Cited by 102
“Normalization of the vessel wall should further decrease leakiness by rectifying abnormal barrier function (25, 26).”
BackgroundInfluentialKesari, S., Schiff, D., Henson, J. W., Muzikansky, A., Gigas, D. C., Doherty, L. M., Batchelor, T. T., Longtine, J. A., Ligon, K. L., Weaver, S., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-005 · Cited by 102
Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Boyle, G. M., D'Souza, M. M. A., Pierce, C. J., Adams, R. A., Cantor, A. S., Johns, J. P., Maslovskaya, L., Gordon, V. A., Reddell, P. W., & Parsons, P. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108887 · Cited by 101
“This specificity may reflect the disorganization and inherent ‘‘leakiness’’ of the vasculature within a solid tumor [32].”
BackgroundHo, Y. T., Kamm, R. D., & Kah, J. C. Y. (2018) · Nanoscale · doi:10.1039/c8nr02393j · Cited by 102
Effect of tumor shape and size on drug delivery to solid tumors
Soltani, M., & Chen, P. (2012) · Journal of Biological Engineering · doi:10.1186/1754-1611-6-4 · Cited by 110
“All of these problems demonstrate that solutions to drug delivery limitations are urgently needed [1].”
BackgroundInfluentialCombined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Pennell, N. A., & Lynch, T. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0276 · Cited by 101
A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer
Moore, K. N., Martin, L. P., O’Malley, D. M., Matulonis, U. A., Konner, J. A., Vergote, I. B., Ponte, J. F., & Birrer, M. J. (2017) · Future Oncology · doi:10.2217/fon-2017-0379 · Cited by 108
Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals
Seo, J.-W., Fu, K. X., Correa, S., Eisenstein, M. S., Appel, E. A., & Soh, H. T. (2022) · Science Advances · doi:10.1126/sciadv.abk2901 · Cited by 110
Crosstalk between angiogenesis and immune regulation in the tumor microenvironment
Kim, H. J., Ji, Y. R., & Lee, Y. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01389-z · Cited by 115
“The strategy in “vascular normalization” is to administer the appropriate dose of angiogenesis inhibitors over a short time frame, with or without co-administration with other anti-cancer drugs during the short period (days to weeks) called the “normalization window” (Jain 2005).”
BackgroundYung, Y. C., Chae, J., Buehler, M. J., Hunter, C. P., & Mooney, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905891106 · Cited by 104
“Significant research in this field has focused on documenting cell response to exogenous biochemical cues, and a variety of growth factors have been identified to have key roles in angiogenesis (2).”
BackgroundBevacizumab-induced diffusion-restricted lesions in malignant glioma patients
Rieger, J., Bähr, O., Müller, K., Franz, K., Steinbach, J. P., & Hattingen, E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0098-8 · Cited by 102
“The normalized vascular permeability of tumor vessels [6] and the reduced microvessel density [14, 15] observable under anti-VEGF treatment may decrease extracellular water content and narrow the extracellular space in relation to the cellular and microvascular compartment, and this is congruent with preclinical studi…”
BackgroundResultHoeppner, L. H., Wang, Y., Sharma, A. K., Javeed, N., Keulen, V. P. V., Wang, E., Yang, P., Roden, A. C., Peikert, T., Molina, J. R., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.008 · Cited by 105
“Jain and colleagues proposed that antiangiogenesis drugs “normalize” the tumor vasculature and temporarily improve blood flow within the tumor, thereby enhancing the efficacy of chemotherapy (Jain, 2005).”
BackgroundHuyghe, N. D., Baldin, P., & den Eynde, M. V. (2019) · Gastroenterology report · doi:10.1093/gastro/goz061 · Cited by 114
Polymeric Nanoparticles for the Treatment of Malignant Gliomas
Mahmoud, B. S., Alamri, A. H., & McConville, C. (2020) · Cancers · doi:10.3390/cancers12010175 · Cited by 110
“The high pressure of the interstitial fluid and dense extracellular matrix hinder the process of diffusion [195,196].”
BackgroundBocci, F., Onuchic, J. N., & Jolly, M. K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00929 · Cited by 109
“Dll1 after wounding but ultimately become followers, showing that the leader-follower differentiation is regulated in a highly dynamical manner by the Notch1-Dll1 pathway (Riahi et al., 2015), similar to the dynamical balance of tip-stalk decisionmaking in angiogenesis (Jakobsson et al., 2010).”
BackgroundNovel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
“, the application of anti-angiogenic therapy to target abnormal tumor vasculature to restore the normal physiological structure of tumor vessels and their ability to supply oxygen and drug transportation [43, 44].”
BackgroundHuang, Y., Snuderl, M., & Jain, R. K. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.005 · Cited by 100
“This positive feedback in the normalized tumor microenvironment may confer an additional advantage: extended window of normalization compared to Cancer Cell blockade of VEGF signaling alone (Jain, 2005; Winkler et al., 2004).”
BackgroundMethodSelf-citationOptimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation
Jain, M., Venkatraman, G., & Batra, S. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2436 · Cited by 109
Baronzio, G., Parmar, G., & Baronzio, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00165 · Cited by 98
“The Concept of Tumor vascular Normalization Jain (111) introduced the concept of normalization of tumor vasculature.”
BackgroundAnti-angiogenesis in cancer therapy: Hercules and hydra
Bellou, S., Pentheroudakis, G. E., Murphy, C., & Fotsis, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.015 · Cited by 105
“However, despite excessive neovascularization, the immature, leaky tumour vasculature often results in high interstitial fluid pressure that actually impedes the blood flow by compressing the remaining tumour vessels further preserving hypoxia [83].”
BackgroundIssues related to targeted delivery of proteins and peptides
Lu, Y. J., Yang, J. J. J., & Sega, E. I. (2006) · The AAPS Journal · doi:10.1208/aapsj080355 · Cited by 99
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
Yuan, T. L., Choi, H. S., Matsui, A., Benes, C., Lifshits, E., Luo, J., Frangioni, J. V., & Cantley, L. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804123105 · Cited by 99
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.